Drug–Drug Interactions of Infectious Disease Treatments in Low‐Income Countries: A Neglected Topic?
Despite recent advances in recognizing and reducing the risk of drug–drug interactions (DDIs) in developed countries, there are still significant challenges in managing DDIs in low‐income countries (LICs) worldwide. In the treatment of major infectious diseases in these regions, multiple factors con...
Gespeichert in:
| Veröffentlicht in: | Clinical pharmacology and therapeutics 2019-06, Vol.105 (6), p.1378-1385 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1385 |
|---|---|
| container_issue | 6 |
| container_start_page | 1378 |
| container_title | Clinical pharmacology and therapeutics |
| container_volume | 105 |
| creator | McFeely, Savannah J. Yu, Jingjing Zhao, Ping Hershenson, Susan Kern, Steven Ragueneau‐Majlessi, Isabelle Hartman, Dan |
| description | Despite recent advances in recognizing and reducing the risk of drug–drug interactions (DDIs) in developed countries, there are still significant challenges in managing DDIs in low‐income countries (LICs) worldwide. In the treatment of major infectious diseases in these regions, multiple factors contribute to ineffective management of DDIs that lead to loss of efficacy or increased risk of adverse events to patients. Some of these difficulties, however, can be overcome. This review aims to evaluate the inherent complexities of DDI management in LICs from pharmacological standpoints and illustrate the unique barriers to effective management of DDIs, such as the challenges of co‐infection and treatment settings. A better understanding of comprehensive drug‐related properties, population‐specific attributes, such as physiological changes associated with infectious diseases, and the use of modeling and simulation techniques are discussed, as they can facilitate the implementation of optimal treatments for infectious diseases at the individual patient level. |
| doi_str_mv | 10.1002/cpt.1397 |
| format | Article |
| fullrecord | <record><control><sourceid>wiley_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6563420</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CPT1397</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4107-9c2723b8af20122c237c86a3bd31ca761bd3b863875cc0a51c50dff5dfa03fe73</originalsourceid><addsrcrecordid>eNp1kM1OAjEUhRujEUQTn8B06WawP3Q640JDwB8Soi5w3ZROizUwJe2MhB2PYOIb8iQWUaILV_ee3HO_e3MAOMWojREiF2petTHN-R5oYkZJkjLK9kETIZQnOaFpAxyF8BplJ8-yQ9CgiHNMGGmCSd_Xk_XqY1PgoKy0l6qyrgzQmaiN3qg6wL4NWgYNR17LaqbLKkBbwqFbrFfvg1K5mYY9V5eVtzpcwi580JNp3NUFHLm5VdfH4MDIadAn37UFnm9vRr37ZPh4N-h1h4nqYMSTXBFO6DiThiBMiCKUqyyVdFxQrCRPcWzGWUozzpRCkmHFUGEMK4xE1GhOW-Bqy53X45kuVPzUy6mYezuTfimctOLvpLQvYuLeRMpS2iEoAs63AOVdCF6b3S5GYhO2iGGLTdjRevb71s74k240JFvDwk718l-Q6D2NvoCfCFuMtw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Drug–Drug Interactions of Infectious Disease Treatments in Low‐Income Countries: A Neglected Topic?</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>McFeely, Savannah J. ; Yu, Jingjing ; Zhao, Ping ; Hershenson, Susan ; Kern, Steven ; Ragueneau‐Majlessi, Isabelle ; Hartman, Dan</creator><creatorcontrib>McFeely, Savannah J. ; Yu, Jingjing ; Zhao, Ping ; Hershenson, Susan ; Kern, Steven ; Ragueneau‐Majlessi, Isabelle ; Hartman, Dan</creatorcontrib><description>Despite recent advances in recognizing and reducing the risk of drug–drug interactions (DDIs) in developed countries, there are still significant challenges in managing DDIs in low‐income countries (LICs) worldwide. In the treatment of major infectious diseases in these regions, multiple factors contribute to ineffective management of DDIs that lead to loss of efficacy or increased risk of adverse events to patients. Some of these difficulties, however, can be overcome. This review aims to evaluate the inherent complexities of DDI management in LICs from pharmacological standpoints and illustrate the unique barriers to effective management of DDIs, such as the challenges of co‐infection and treatment settings. A better understanding of comprehensive drug‐related properties, population‐specific attributes, such as physiological changes associated with infectious diseases, and the use of modeling and simulation techniques are discussed, as they can facilitate the implementation of optimal treatments for infectious diseases at the individual patient level.</description><identifier>ISSN: 0009-9236</identifier><identifier>EISSN: 1532-6535</identifier><identifier>DOI: 10.1002/cpt.1397</identifier><identifier>PMID: 30771252</identifier><language>eng</language><publisher>United States: John Wiley and Sons Inc</publisher><subject>Anti-Infective Agents - economics ; Anti-Infective Agents - metabolism ; Anti-Infective Agents - therapeutic use ; Antitubercular Agents - economics ; Antitubercular Agents - metabolism ; Antitubercular Agents - therapeutic use ; Communicable Diseases - drug therapy ; Communicable Diseases - economics ; Communicable Diseases - metabolism ; Drug Interactions - physiology ; Humans ; Poverty - economics ; Poverty - trends ; Reviews ; State of the Art ; Treatment Outcome ; Tuberculosis - drug therapy ; Tuberculosis - economics ; Tuberculosis - metabolism</subject><ispartof>Clinical pharmacology and therapeutics, 2019-06, Vol.105 (6), p.1378-1385</ispartof><rights>2019 The Authors published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics</rights><rights>2019 The Authors Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4107-9c2723b8af20122c237c86a3bd31ca761bd3b863875cc0a51c50dff5dfa03fe73</citedby><cites>FETCH-LOGICAL-c4107-9c2723b8af20122c237c86a3bd31ca761bd3b863875cc0a51c50dff5dfa03fe73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcpt.1397$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcpt.1397$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30771252$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>McFeely, Savannah J.</creatorcontrib><creatorcontrib>Yu, Jingjing</creatorcontrib><creatorcontrib>Zhao, Ping</creatorcontrib><creatorcontrib>Hershenson, Susan</creatorcontrib><creatorcontrib>Kern, Steven</creatorcontrib><creatorcontrib>Ragueneau‐Majlessi, Isabelle</creatorcontrib><creatorcontrib>Hartman, Dan</creatorcontrib><title>Drug–Drug Interactions of Infectious Disease Treatments in Low‐Income Countries: A Neglected Topic?</title><title>Clinical pharmacology and therapeutics</title><addtitle>Clin Pharmacol Ther</addtitle><description>Despite recent advances in recognizing and reducing the risk of drug–drug interactions (DDIs) in developed countries, there are still significant challenges in managing DDIs in low‐income countries (LICs) worldwide. In the treatment of major infectious diseases in these regions, multiple factors contribute to ineffective management of DDIs that lead to loss of efficacy or increased risk of adverse events to patients. Some of these difficulties, however, can be overcome. This review aims to evaluate the inherent complexities of DDI management in LICs from pharmacological standpoints and illustrate the unique barriers to effective management of DDIs, such as the challenges of co‐infection and treatment settings. A better understanding of comprehensive drug‐related properties, population‐specific attributes, such as physiological changes associated with infectious diseases, and the use of modeling and simulation techniques are discussed, as they can facilitate the implementation of optimal treatments for infectious diseases at the individual patient level.</description><subject>Anti-Infective Agents - economics</subject><subject>Anti-Infective Agents - metabolism</subject><subject>Anti-Infective Agents - therapeutic use</subject><subject>Antitubercular Agents - economics</subject><subject>Antitubercular Agents - metabolism</subject><subject>Antitubercular Agents - therapeutic use</subject><subject>Communicable Diseases - drug therapy</subject><subject>Communicable Diseases - economics</subject><subject>Communicable Diseases - metabolism</subject><subject>Drug Interactions - physiology</subject><subject>Humans</subject><subject>Poverty - economics</subject><subject>Poverty - trends</subject><subject>Reviews</subject><subject>State of the Art</subject><subject>Treatment Outcome</subject><subject>Tuberculosis - drug therapy</subject><subject>Tuberculosis - economics</subject><subject>Tuberculosis - metabolism</subject><issn>0009-9236</issn><issn>1532-6535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp1kM1OAjEUhRujEUQTn8B06WawP3Q640JDwB8Soi5w3ZROizUwJe2MhB2PYOIb8iQWUaILV_ee3HO_e3MAOMWojREiF2petTHN-R5oYkZJkjLK9kETIZQnOaFpAxyF8BplJ8-yQ9CgiHNMGGmCSd_Xk_XqY1PgoKy0l6qyrgzQmaiN3qg6wL4NWgYNR17LaqbLKkBbwqFbrFfvg1K5mYY9V5eVtzpcwi580JNp3NUFHLm5VdfH4MDIadAn37UFnm9vRr37ZPh4N-h1h4nqYMSTXBFO6DiThiBMiCKUqyyVdFxQrCRPcWzGWUozzpRCkmHFUGEMK4xE1GhOW-Bqy53X45kuVPzUy6mYezuTfimctOLvpLQvYuLeRMpS2iEoAs63AOVdCF6b3S5GYhO2iGGLTdjRevb71s74k240JFvDwk718l-Q6D2NvoCfCFuMtw</recordid><startdate>201906</startdate><enddate>201906</enddate><creator>McFeely, Savannah J.</creator><creator>Yu, Jingjing</creator><creator>Zhao, Ping</creator><creator>Hershenson, Susan</creator><creator>Kern, Steven</creator><creator>Ragueneau‐Majlessi, Isabelle</creator><creator>Hartman, Dan</creator><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>201906</creationdate><title>Drug–Drug Interactions of Infectious Disease Treatments in Low‐Income Countries: A Neglected Topic?</title><author>McFeely, Savannah J. ; Yu, Jingjing ; Zhao, Ping ; Hershenson, Susan ; Kern, Steven ; Ragueneau‐Majlessi, Isabelle ; Hartman, Dan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4107-9c2723b8af20122c237c86a3bd31ca761bd3b863875cc0a51c50dff5dfa03fe73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Anti-Infective Agents - economics</topic><topic>Anti-Infective Agents - metabolism</topic><topic>Anti-Infective Agents - therapeutic use</topic><topic>Antitubercular Agents - economics</topic><topic>Antitubercular Agents - metabolism</topic><topic>Antitubercular Agents - therapeutic use</topic><topic>Communicable Diseases - drug therapy</topic><topic>Communicable Diseases - economics</topic><topic>Communicable Diseases - metabolism</topic><topic>Drug Interactions - physiology</topic><topic>Humans</topic><topic>Poverty - economics</topic><topic>Poverty - trends</topic><topic>Reviews</topic><topic>State of the Art</topic><topic>Treatment Outcome</topic><topic>Tuberculosis - drug therapy</topic><topic>Tuberculosis - economics</topic><topic>Tuberculosis - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McFeely, Savannah J.</creatorcontrib><creatorcontrib>Yu, Jingjing</creatorcontrib><creatorcontrib>Zhao, Ping</creatorcontrib><creatorcontrib>Hershenson, Susan</creatorcontrib><creatorcontrib>Kern, Steven</creatorcontrib><creatorcontrib>Ragueneau‐Majlessi, Isabelle</creatorcontrib><creatorcontrib>Hartman, Dan</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Online Library Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McFeely, Savannah J.</au><au>Yu, Jingjing</au><au>Zhao, Ping</au><au>Hershenson, Susan</au><au>Kern, Steven</au><au>Ragueneau‐Majlessi, Isabelle</au><au>Hartman, Dan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Drug–Drug Interactions of Infectious Disease Treatments in Low‐Income Countries: A Neglected Topic?</atitle><jtitle>Clinical pharmacology and therapeutics</jtitle><addtitle>Clin Pharmacol Ther</addtitle><date>2019-06</date><risdate>2019</risdate><volume>105</volume><issue>6</issue><spage>1378</spage><epage>1385</epage><pages>1378-1385</pages><issn>0009-9236</issn><eissn>1532-6535</eissn><abstract>Despite recent advances in recognizing and reducing the risk of drug–drug interactions (DDIs) in developed countries, there are still significant challenges in managing DDIs in low‐income countries (LICs) worldwide. In the treatment of major infectious diseases in these regions, multiple factors contribute to ineffective management of DDIs that lead to loss of efficacy or increased risk of adverse events to patients. Some of these difficulties, however, can be overcome. This review aims to evaluate the inherent complexities of DDI management in LICs from pharmacological standpoints and illustrate the unique barriers to effective management of DDIs, such as the challenges of co‐infection and treatment settings. A better understanding of comprehensive drug‐related properties, population‐specific attributes, such as physiological changes associated with infectious diseases, and the use of modeling and simulation techniques are discussed, as they can facilitate the implementation of optimal treatments for infectious diseases at the individual patient level.</abstract><cop>United States</cop><pub>John Wiley and Sons Inc</pub><pmid>30771252</pmid><doi>10.1002/cpt.1397</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-9236 |
| ispartof | Clinical pharmacology and therapeutics, 2019-06, Vol.105 (6), p.1378-1385 |
| issn | 0009-9236 1532-6535 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6563420 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Anti-Infective Agents - economics Anti-Infective Agents - metabolism Anti-Infective Agents - therapeutic use Antitubercular Agents - economics Antitubercular Agents - metabolism Antitubercular Agents - therapeutic use Communicable Diseases - drug therapy Communicable Diseases - economics Communicable Diseases - metabolism Drug Interactions - physiology Humans Poverty - economics Poverty - trends Reviews State of the Art Treatment Outcome Tuberculosis - drug therapy Tuberculosis - economics Tuberculosis - metabolism |
| title | Drug–Drug Interactions of Infectious Disease Treatments in Low‐Income Countries: A Neglected Topic? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T10%3A41%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Drug%E2%80%93Drug%20Interactions%20of%20Infectious%20Disease%20Treatments%20in%20Low%E2%80%90Income%20Countries:%20A%20Neglected%20Topic?&rft.jtitle=Clinical%20pharmacology%20and%20therapeutics&rft.au=McFeely,%20Savannah%20J.&rft.date=2019-06&rft.volume=105&rft.issue=6&rft.spage=1378&rft.epage=1385&rft.pages=1378-1385&rft.issn=0009-9236&rft.eissn=1532-6535&rft_id=info:doi/10.1002/cpt.1397&rft_dat=%3Cwiley_pubme%3ECPT1397%3C/wiley_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/30771252&rfr_iscdi=true |